Blood pressure pill joins fight against tough head & neck cancers
NCT ID NCT06211335
Summary
This early-stage study is testing if a three-part treatment is safe and effective for people with head and neck cancer that has come back, spread a little, or hasn't responded to other treatments. The treatment combines a common blood pressure drug (losartan), an immunotherapy drug (pembrolizumab), and very precise, high-dose radiation (SBRT). Researchers hope this combination will help the immune system better attack the cancer and improve outcomes for these difficult-to-treat cases.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California Davis Comprehensive Cancer Center
RECRUITINGSacramento, California, 95817, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Colorado Denver | Anschutz Medical Campus
RECRUITINGAurora, Colorado, 80045, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.